189 related articles for article (PubMed ID: 38631708)
1. Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.
Razmara AM; Farley LE; Harris RM; Judge SJ; Lammers M; Iranpur KR; Johnson EG; Dunai C; Murphy WJ; Brown CT; Rebhun RB; Kent MS; Canter RJ
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631708
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.
Canter RJ; Grossenbacher SK; Foltz JA; Sturgill IR; Park JS; Luna JI; Kent MS; Culp WTN; Chen M; Modiano JF; Monjazeb AM; Lee DA; Murphy WJ
J Immunother Cancer; 2017 Dec; 5(1):98. PubMed ID: 29254507
[TBL] [Abstract][Full Text] [Related]
3. Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer.
Judge SJ; Yanagisawa M; Sturgill IR; Bateni SB; Gingrich AA; Foltz JA; Lee DA; Modiano JF; Monjazeb AM; Culp WTN; Rebhun RB; Murphy WJ; Kent MS; Canter RJ
PLoS One; 2020; 15(2):e0224775. PubMed ID: 32084139
[TBL] [Abstract][Full Text] [Related]
4. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Phenotypic and Functional Characteristics Between Canine Non-B, Non-T Natural Killer Lymphocytes and CD3
Lee SH; Shin DJ; Kim Y; Kim CJ; Lee JJ; Yoon MS; Uong TNT; Yu D; Jung JY; Cho D; Jung BG; Kim SK; Suh GH
Front Immunol; 2018; 9():841. PubMed ID: 29755462
[TBL] [Abstract][Full Text] [Related]
6. Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target.
Gingrich AA; Reiter TE; Judge SJ; York D; Yanagisawa M; Razmara A; Sturgill I; Basmaci UN; Brady RV; Stoffel K; Murphy WJ; Rebhun RB; Brown CT; Canter RJ
Front Immunol; 2021; 12():670309. PubMed ID: 34594320
[TBL] [Abstract][Full Text] [Related]
7. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
8. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
Front Immunol; 2019; 10():2816. PubMed ID: 31849984
[TBL] [Abstract][Full Text] [Related]
9. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor.
Sutlu T; Stellan B; Gilljam M; Quezada HC; Nahi H; Gahrton G; Alici E
Cytotherapy; 2010 Dec; 12(8):1044-55. PubMed ID: 20795758
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy.
Yang HG; Kang MC; Kim TY; Hwang I; Jin HT; Sung YC; Eom KS; Kim SW
J Immunother Cancer; 2019 May; 7(1):138. PubMed ID: 31126350
[TBL] [Abstract][Full Text] [Related]
11. Safety analysis of ex vivo-expanded canine natural killer cells in a xenogeneic mouse model of graft-versus-host disease.
Kim CJ; Park SC; Lee SH; Lim YJ; Yoon M; Park JG; Baek YB; Cho KO; Hong JW; Shin DJ; Kim SK
J Leukoc Biol; 2022 Feb; 111(2):439-450. PubMed ID: 33884654
[TBL] [Abstract][Full Text] [Related]
12. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
[TBL] [Abstract][Full Text] [Related]
13. Irradiated and activated autologous PBMCs induce expansion of highly cytotoxic human NK cells in vitro.
Ahn YO; Kim S; Kim TM; Song EY; Park MH; Heo DS
J Immunother; 2013 Sep; 36(7):373-81. PubMed ID: 23924789
[TBL] [Abstract][Full Text] [Related]
14. NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells.
Foltz JA; Somanchi SS; Yang Y; Aquino-Lopez A; Bishop EE; Lee DA
Front Immunol; 2016; 7():521. PubMed ID: 27933061
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer.
Choi JW; Lee ES; Kim SY; Park SI; Oh S; Kang JH; Ryu HA; Lee S
BMC Cancer; 2019 Aug; 19(1):817. PubMed ID: 31426763
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies.
Masuyama J; Murakami T; Iwamoto S; Fujita S
Cytotherapy; 2016 Jan; 18(1):80-90. PubMed ID: 26549384
[TBL] [Abstract][Full Text] [Related]
17. Selection and expansion of natural killer cells for NK cell-based immunotherapy.
Becker PS; Suck G; Nowakowska P; Ullrich E; Seifried E; Bader P; Tonn T; Seidl C
Cancer Immunol Immunother; 2016 Apr; 65(4):477-84. PubMed ID: 26810567
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells.
Shin DJ; Park JY; Jang YY; Lee JJ; Lee YK; Shin MG; Jung JY; Carson WE; Cho D; Kim SK
Vet Immunol Immunopathol; 2013 Jun; 153(3-4):249-59. PubMed ID: 23548866
[TBL] [Abstract][Full Text] [Related]
19. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
20. Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells.
Pandey V; Oyer JL; Igarashi RY; Gitto SB; Copik AJ; Altomare DA
Oncotarget; 2016 Feb; 7(6):7318-28. PubMed ID: 26802025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]